Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024Market Watch • 01/09/24
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/08/24
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host DiseaseBusiness Wire • 12/10/23
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual MeetingBusiness Wire • 11/02/23
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 10/31/23
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023Business Wire • 10/16/23
Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in BrazilGlobeNewsWire • 10/16/23
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic DermatitisBusiness Wire • 10/13/23
Data From Incyte's Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)Business Wire • 10/13/23